Look­ing to bat­tle ri­vals in a big mar­ket, Ab­b­Vie is head­ed to the FDA af­ter clear­ing a PhI­II hur­dle for chron­ic mi­graine

Ever the ag­gres­sive com­peti­tor, Ab­b­Vie is tak­ing a shot at a sig­nif­i­cant la­bel ex­pan­sion for its mi­graine drug Qulip­ta (ato­gepant) that will give them a leg up in the race against Bio­haven’s mar­ket-lead­ing ri­val Nurtec.

The phar­ma gi­ant re­port­ed to­day that its lat­est Phase III study proved that a dai­ly 60 mg dose as well as a twice-dai­ly 30 mg dose of Qulip­ta — green-light­ed for treat­ing episod­ic mi­graine last fall — worked in pre­vent­ing chron­ic mi­graine, sig­nif­i­cant­ly re­duc­ing the num­ber of mi­graines ex­pe­ri­enced by the tar­get group of pa­tients com­pared to place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER